Navigation Links
Genzyme Announces Results of Clinical Trials Investigating Powder,Form of Sevelamer Carbonate

sified enterprise with more than 9,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. Genzyme has been selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme(R) and Renagel(R) are registered trademarks and Renvela(TM) is a trademark of Genzyme Corporation. All rights reserved.

This press release contains forward-looking statements including, without limitation, statements about the development of Renvela(TM) for chronic kidney disease and alternative dosing regimens for the powder formulation of Renvela(TM). These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: additional analysis of the data comparing the powder form of Renvela(TM) to Renagel(R); the results of other studies and whether such results are consistent with this data; the actual efficacy and safety of Renvela(TM) for chronic kidney disease; the outcome of discussions with regulatory authorities regarding clinical studies and the approval of Renvela(TM) for chronic kidney disease and the timing of such discussions; the timing and content of submissions to and decisions made by regulatory authorities; the availability and extent of third-party reimbursement for Renvela(TM); and the risks and uncertainties described i
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
5. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:3/27/2015)... , March 27, 2015 Concord ... "Company") (NYSE: CCM ), a leading specialty ... largest network of radiotherapy and diagnostic imaging centers ... the signing of a purchase agreement under which ... owned subsidiary of the Company, agreed to acquire ...
(Date:3/26/2015)... /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the ... Omega-3 therapies for cardiovascular disease and overall health, announced ... shares of the Corporation (the "Common Shares"). The Common ... December 5 th , 2014 to March 4 th ... due on or before April 1, 2015. Interest on ...
(Date:3/26/2015)... BOTHELL, Wash. and VANCOUVER, British Columbia, March 26, ... ) today provided a summary of clinical developments ... financial results. Clinical Developments and ... December 2014, OncoGenex and Teva agreed to negotiate ... rights to OncoGenex. Negotiations of the final termination ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... today released a letter from its President Mario H. Lopez, ... dispute. At a critical time in our nation,s ... in danger of having health care choices severely affected by ... The text of the letter follows: ...
... KNSY ) today announced that it has agreed ... an attempt to resolve disputes over royalty payments to Kensey ... as other related claims. Kensey Nash has repeatedly advised St. ... should since 2007 have been paid, at a rate of ...
Cached Medicine Technology:Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 2Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 3Kensey Nash to Enter Into Mediation with St. Jude Medical over Angio-Seal Contract Disputes 4
(Date:3/27/2015)... 2015 Endure Yoga is launching WOD ... athletes. This new program matches yoga poses with functional ... cool down. This program utilizes yoga to improve recovery, ... focus. , Karen Lefurgy, competitive athlete at ... before I started Crossfit® training, but quickly, due to ...
(Date:3/27/2015)... 2015 GenSight, the leading Enterprise Portfolio ... Fitzgerald, a former technology and financial executive to serve ... Chief Financial Officer. , Mr Fitzgerald was most recently ... backed by Amazon founder and CEO Jeff Bezos, Google ... to EverFi, he was a Senior Vice President at ...
(Date:3/27/2015)... Grants Pass, OR (PRWEB) March 27, 2015 ... record breaking winter blizzards in Boston and the United ... climate change patterns. Earth warming global atmosphere is creating ... DeWayne Cecil, PhD, historical climatologist and former NASA researcher, ... radio show. The result is not only a warmer ...
(Date:3/27/2015)... CT (PRWEB) March 27, 2015 Trail mix ... after a workout, on weekend hikes and during the game! ... benefits. Aurora Natural is proud to introduce a new line ... taste buds. Deliciously rich and flavorful selections packed with nutritious, ... seeds, dried fruit and grains that add protein and fiber ...
(Date:3/27/2015)... March 27, 2015 The 2015 ... is a professional and in-depth study on the ... with a focus on the Chinese situation. ... the industry including definitions, classifications, applications and industry ... for both the international and Chinese domestic situations ...
Breaking Medicine News(10 mins):Health News:Endure Yoga Introduces WOD Recovery Yoga 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Aurora Product, Inc. Introduces New Line of Specialty Trail Mixes 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... David and Lucile Packard Foundation,announce new projects supporting ... WASHINGTON, Feb. 6 The Robert Wood Johnson,Foundation ... (Packard),each announced grant projects today that will considerably ... of the nation,s most pressing health care,problems are ...
... (OTC Bulletin Board: GXYF), a leading developer and marketer ... food,products, today announced that it will host an investor ... for the 2008 fiscal year at,11:00 a.m. EST on ... its,operating results before the market opens the same day., ...
... seek restatement of Beth Israel Deaconess,Medical Center audit, ... director Stephen Chubb should apply the same Sarbanes-Oxley,standards ... traded,companies to his role on the board of ... Center (BIDMC), according to labor group 1199,SEIU United ...
... Register Now - Space is Limited, BOSTON, Feb. ... an innovative and timely,course that will be presented under ... The course, which will be held,at the Omni Parker ... is a,follow-up to a successful 2006 event that attracted ...
... in a large, multi-institutional study comparing the accuracy of ... the characterization of lung nodules found that PET was ... nodule was malignant. , CT and PET have been ... benign or malignant, said James W. Fletcher, professor of ...
... Quarter 2008 Sees 52 Percent Increase in Sales from Same ... ... Greenway Medical Technologies,Inc., a leading provider of integrated electronic health records ... its second quarter of fiscal 2008, ending,December 31, 2007, were up ...
Cached Medicine News:Health News:Foundations to Strengthen State Health Care Reform Advocacy 2Health News:Foundations to Strengthen State Health Care Reform Advocacy 3Health News:Foundations to Strengthen State Health Care Reform Advocacy 4Health News:Galaxy Nutritional Foods Announces Third Quarter FY2008 Earnings Conference Call for Friday, February 8, 2008 2Health News:Charles River Laboratories International Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:Innovative eHealth Course to Take Place March 28-30 in Boston, Massachusetts 2Health News:PET outperforms CT in characterization of lung nodules 2Health News:Greenway Medical Technologies Continues Record Setting Growth 2Health News:Greenway Medical Technologies Continues Record Setting Growth 3Health News:Greenway Medical Technologies Continues Record Setting Growth 4
... / MVR knife. 1.1 mm (19G) with a ... (19G) Cannula (5/bx, 1 bx/ca). State-of-the-art manufacturing and ... and precise. Sure grip handles have a ridge ... a fluid tight incision for self-sealing wounds. Gauge ...
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... Renu Multiplus preservative free ... and moisturize your eyes while ... The gentle preservative free formula ... may be sensitive to preservatives ...
Medicine Products: